Pfizer and BioNTech are launching a clinical trial to test an omicron-specific version of their COVID-19 vaccine, the companies announced today. They’re moving forward with studies of a new form of the vaccine in response to concerns that the original shot isn’t preventing infection with the newest variant of coronavirus or mild COVID-19 illness — even though it appears to be holding up well in terms of preventing hospitalization...
More on Upstract
